Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The genomics of new drugs in sickle cell disease.

Pharmacogenomics - 1 Sept 2006

Makis Alexandros C, Hatzimichael Eleftheria C, Stebbing Justin

Abstract excerpt

The quality of life of patients with sickle cell disease in developed countries has improved significantly over the past two decades. Currently available measures to prevent the painful crises and the complications of the disease include the use of penicillin prophylaxis, antipneumonococcal vaccine, folate administration, chronic red cell transfusions in patients with cerebrovascular disease, iron chelating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Azacitidine
Share to Butyrates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Hydroxyurea

Share to Nitric Oxide

Share to Pharmacogenetics

Share to Toxicogenetics

Source

Identifiers

PMID: 16981849
DOI: 10.2217/14622416.7.6.909

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The genomics of new drugs in sickle cell disease.PMID 16981849Read ↗

Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical ApplicationsSemantic proximity Read ↗

Hydroxyurea in the sickle cell disease modern eraSemantic proximity Read ↗

Is there a role for pharmacogenetics in the treatment of sickle cell disease?Semantic proximity Read ↗

Sickle Cell Disease, a ReviewSemantic proximity Read ↗

Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolismSemantic proximity Read ↗

An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision MedicineSemantic proximity Read ↗

Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach.Semantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

The future of sickle cell disease therapeutics rests in genomicsSemantic proximity Read ↗

Drug Therapies for the Management of Sickle Cell DiseaseSemantic proximity Read ↗

Pharmacogenomics and therapeutics of hemoglobinopathies.Semantic proximity Read ↗

Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine ApproachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.